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1. Introduction   
Wilson's disease (WD) is an inherited disorder of copper metabolism first defined by Dr 
Samuel Alexander Kinnier Wilson in 1912 (Wilson, 1912). WD is caused by mutations to the 
gene coding for ATPase copper transporting beta polypeptide (ATP7B), which is located on 
13 chromosome 13 and expressed in the liver (Bull et al.,1993; Loudianos et al.,1999; 
Yamaguchi et al.,1993; Frydman et al., 1985). The disease is inherited in an autosomal 
recessive manner.  
WD is present worldwide in most populations, and particularly in those in which 
consanguineous marriage is common. The disease frequency is estimated to be between 1 in 
5,000 and 1 in 30,000, and the heterozygous carriers (Hzc) frequency is approximately 1 in 90 
(Figus et al., 1995).  
In the ATP7B gene of WD a variety of mutations were defected. These defects include 
insertion, deletion, splice site and point mutations. In most ethnic groups, one or a small 
number of these ATP7B gene mutations are predominant, in addition to many other rare 
mutations. In Europeans and North Americans, two ATP7B point mutations: His1069Gln 
and Gly1267Arg account for 38% of mutations described in WD (Thomas et al., 1995). There 
is still no favorable correlation between phenotype and genotype, but frame shift deletions 
and nonsense mutations that cause a truncation of the translated protein product usually 
result in a severe form of the disease because of loss of the functional protein. The 
knowledge of the prevalence of mutations is helpful in achieving rapid mutational 
screening. Mutations in ATP7B cause a reduction in the conversion of apoceruloplasmin into 
ceruloplasmin, which, is therefore  present at low levels in WD patients.  
A failure to excrete copper into the biliary canaliculi leads to its toxic accumulation in the 
hepatocytes (Schilsky&Tavill, 2003). The copper excess may damage hepatic mitochondria 
and oxidative damage to hepatic cells and cause the spillage of copper into the blood, 
thereby overloading other organs such as the brain, kidney and red blood cells, initiating 
toxic damage (Schilsky&Tavill, 2003). In the early stages of WD diffuse  cytoplasmic copper 
accumulation can be seen only by special immunohistochemical stains for copper detecting. 
The early accumulation of copper is associated with hepatic steatosis. The ultrastructural 
abnormalities range from enlargement and separation of the mitochondrial inner and  outer 
membranes with widening of the  intercristal spaces, to increases in the density and 
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granularity of the matrix. During the disease progression periportal inflammation 
mononuclear cellular infiltration lobular necrosis and bridging fibrosis occur.  The areas of 
the brain main affected in WD are the basal ganglia (lenticular nuclei), which 
macroscopically appear brown in color because of copper deposition (Scheinberg& 
Sternlieb, 1984).  In the early stages of the WD, proliferation of large protoplasmic astrocytes 
such as Opalski cells and Alzheimer cells occurs. During the disease progression the 
degeneration occurs leading to necrosis, gliosis and cystic changes. The degeneration can be 
seen in the brainstem, thalamus, cerebellum and cerebral cortex. During the WD 
progression, copper deposits can lead to vacuolar degeneration in proximal renal tubular 
cells, appearance of the 'Kayser–Fleischer' (KF) ring in Descemet's membrane. Copper from 
the hepatic cells degradation can be released into the circulation and can damage red blood 
cells, thereby inducing hemolysis (Schilsky&Tavill, 2003).  
The majority of patients with WD present or with hepatic or neuropsychiatric symptoms, 
and with either clinically asymptomatic or symptomatic liver involvement. The remaining 
patients, may present with symptoms attributable to the involvement of other organs, as 
acute non-immunological hemolytic anemia, osteoarthritis, arrhythmias, rheumatic-fever-
like manifestation, renal function abnormalities, primary or secondary amenorrhea, 
repeated and unexplained spontaneous abortions. Patients with hepatic WD (hWD) usually 
present in late childhood or adolescence, and exhibit features of acute hepatitis, fulminant 
hepatic failure, or progressive chronic liver disease in the form of either chronic active 
hepatitis or cirrhosis of the macronodular type (Schilsky&Tavill, 2003;. Hoogenraad, 1997). 
The mean age of onset of neurological WD (nWD) is the second to third decade 
(Hoogenraad, 1997). Most of patients present with extrapyramidal, cerebellar and cerebral-
related symptoms. Tremor, gait and speech disturbances are the most common initial 
presentation symptoms. Patients may present also present with dystonia. About 30% of 
patients experience psychiatric disturbances (Hoogenraad, 1997).  These disturbances can 
manifest as changes in school-related or work-related performance, attention deficit 
hyperactivity disorder, impulsivity, paranoid psychosis, obsessive behavior, depression, 
suicidal tendencies or bizarre behavior, and can occur early or late in the disease course.  
The WD diagnosis and monitoring is based on history, physical, biochemical, liver biopsy 
and genetic mutations and imaging assessment.  The KF ring is an important marker in 
nWD examination. The WD is biochemically characterized by low ceruloplasmin and total 
serum copper levels, increased 24-hour urinary copper excretion, and abnormally high 
hepatic copper content in the liver biopsy particularly in children performed. Another  
noninvasive method for assessing copper metabolism is incorporation of radioactive copper 
into the hepatocytes used with favorable results in Poland specially in presymptomatic gene 
mutation carriers, siblings of WD patients diagnosis (Członkowska et al. , 1973). The 
mutation screening to identify defects in the ATP7B gene can confirmation of WD diagnosis, 
but will not necessarily detect all disease producing mutations.  
2. Neuroimaging 
2.1 Magnetic resonance imaging 
Neuroimaging plays an important role in the diagnosis and monitoring of WD patients. In 
brain CT scans hypodensities and atrophy of the bilateral basal ganglia, brainstem, 
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cerebellum and cerebral cortex can be seen (Hoogenraad, 1997). MRI is much more sensitive 
method for revealing abnormalities in WD (Hoogenraad, 1997;. Sinha et al., 2006). On T1-
weighted images, generalized brain atrophy is seen in about 75% of cases, and 
hypointensities in the basal ganglia. On T2-weighted images, hyperintensity in the basal 
ganglia, white matter, thalamus or brainstem can be seen (Figure 1). These abnormalities are 
caused by neuronal loss, gliosis, degeneration of fibers, and vacuolization associated with 
increased water content in the brain. Signal abnormalities vary according to the stage of the 
disease, and can be reversible with therapy in the early stages. In some cases, T2-weighted 
images show hypointensity in the basal ganglia (globus pallidus) region may be as a result 
of deposition of iron in exchange for copper after chelation (Figure 2).  
In some WD patients with WD MRI shows a typical pallidal hyperintensity on T1-weighted 
images (Cordoba et al., 2003) (Figure 3). This abnormality appears to be secondary to the 
accumulation of manganese in basal ganglia because of portal-systemic shunting (Cordoba 
et al., 2003). 
  
Fig. 1. Axial T2 - weighed MRI image of a 31- years – old men with WD, MRI was done 
before treatment. The picture shows bilateral hyperintensities in putamen, caudatum and 
thalami and degree of diffuse brain atrophy.  
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Fig. 2. Axial T2 - weighed MRI image of a 47- years – old women with WD treated for more 
than 10 years. The picture shows  persistent hyperintensities in putamen, caudatum globus 
pallidus and degree of diffuse brain atrophy and  hypointensity in the basal ganglia.  
Proton Magnetic Resonance spectroscopy (1H-MRS) is a practical  research tool for 
elucidating the pathophysiology underlying certain diseases (Rudkin & Arnold, 1999). In 
patients with hepatic encephalopathy (HE), 1H-MRS has been used to detect metabolic 
abnormalities in the brain with very high sensitivity (Ross et al., 1999). The biochemical 
alterations that were detected in HE included an increase in cerebral glutamine compounds 
(Glx) and a decrease in myoinositol (mI) and choline (Cho) metabolites (Cordoba et al., 
2002). Other metabolites detectable in vivo by 1H-MRS are N-acetylaspartate (NAA), 
considered to be a marker of neuronal health, and creatine (Cr), often used as an internal 
standard against which the resonance intensities of other metabolites are normalized. The 
role of NAA in nervous system can be related to: action as an organic osmolyte that counters 
the “anion deficit” in neurons, or a cotransport substrate for a proposed “molecular water 
pump” that removes metabolic water from neurons; NAA is a precursor for the enzyme-
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mediated neuronal dipeptide N-acetylaspartylglutamate biosynthesis; NAA provides a 
source of acetate for myelin lipid synthesis and is involved in energy metabolism in 
neuronal mitochondria-reflect improvement of neuronal energetic (Moffett et al.,2007).   
 
Fig. 3. Axial T1 - weighed MRI image of a 45- years – old WD patient with hepatic cirrhosis 
with subclinical hepatic encephalopathy. 
1H-MRS is a technique that could help distinguish between brain changes caused by HE and 
those related to copper toxicosis in WD.  To elucidate the pathomechanism of the cerebral 
pathology of WD a study using 1H-MRS in 37 newly diagnosed WD patients in the globus 
pallidus and thalamus examined bilaterally was performed (Tarnacka et al, 2009a). The 
calculations were performed for: mI, Cho, creatine (Cr), NAA, lipid (Lip), Glx. In all WD 
patients a significantly decreased mI/Cr and NAA/Cr ratio level and an increased Lip/Cr 
ratio in the pallidum was observed. Analysis revealed a significantly increased Glx/Cr and 
Lip/Cr ratio in the thalamus. In the pallidum of nWD patients, Cho/Cr and Glx/Cr and 
Lip/Cr ratios were higher than in control subjects, and the NAA/Cr was significantly lower 
(Table 1). In hWD patients, the mI/Cr and Cho/Cr and NAA/Cr ratio levels were lower 
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than in controls (Table 1). The Cho/Cr and Lip/Cr ratios were higher in the thalami of nWD 
patients, and Lip/Cr ratios were higher than controls’ in patients only with hWD. On the 
Figure 4 the examples of 1H-MRS spectra in nWD and hWD and presymptomatic patients 
compared with control subjects are provided.  
 
Patients: mI/Cr Cho/Cr Glx/Cr NAA/Cr Lip/Cr 
nWD 0,66  0,31 0,89  0,30* 1,26  0,51* 1,43  0,42 ¥¶ 0,94  0,46* 
hWD 0,50  0,27¶¥ 0,68  0,24¶ 1,38  0,39* 1,36  0,39¶¥ 0,81  0,31* 
presymptomatic 0,35  0,10 0,66  0,09 1,37  0,24 1,59  0,14 0,65  0,08 
Control group 0,72  0,15 0,78  0,15 1,11  0,25 1,61  0,26 0,47  0,20 
1 H-MRS study pallidum  
 
Patients: mI/Cr Cho/Cr Glx/Cr NAA/Cr Lip/Cr 
nWD 0,74 0,30 1.01  0,27* 1,19  0,32 1,91  0,56 0,74  0,32* 
hWD 0,85  0,27 1.07  0,24 1.21  0,39 1,73  0,39 0.78  0,31* 
presymptomatic 0,760,21 0,910,23 1,130,20 1,690,32 0,500,22 
Control group 0,82  0.20 0,83  0,14 1,11  0,21 1,68  0,24 0,50  0,20 
1 H-MRS.thalamus 
*statistically higher than in control group  
¶ statistically lower than in control group  
¥  statistically lower compared with thalami 
Table 1. The mean relative metabolic ratios in (left and right) pallidum and (right and left) 
thalamus in neurological (nWD) and hepatic (hWD) and presymptomatic subgroups. 
 
 
Fig. 4. a. 1H-MRS images of patient with hepatic WD presentation compared with control 
subject. Proton spectrum shows expression of Glx; Cho and NAA were significantly 
reduced. The axial image shows the inset from where the spectrum was recorded.  
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Fig. 4. b. 1H-MRS images of patient with neurological WD presentation compared with 
control subject. Proton spectrum shows expression of Glx, Lip; NAA was significantly 
reduced. The axial image shows the inset from where the spectrum was recorded.  
 
 
Fig. 4. c. 1H-MRS images of presymptomatic WD patients compared with control subject. 
Proton spectrum shows expression of Lip; Cr was significantly reduced. The axial image 
shows the inset from where the spectrum was recorded.  
www.intechopen.com
 Magnetic Resonance Spectroscopy 
 
80
In those study the thalamic changes compared with the basal ganglia were more sensitive to 
ongoing degenerative changes and portal-systemic encephalopathy.  
Spectroscopic changes in presymtomatic patients were performed only on 4 cases, because 
of it was very difficult to find patients, who did not have any clinical and biochemical (liver 
failure) abnormalities. In those patients significantly lower levels of mI/Cr and Cho/Cr and 
increase of Glx/Cr ratios in basal ganglia. In thalami no changes were seen. Those findings 
can suggest that in presymptomatic patients in MRS early encephalopatic changes with 
decrease of mI can be noticed.  
The decreased Cho/Cr and mI/Cr in the pallidum of hWD patients could be indicative of 
minimal HE. Mioinositol is one of the chief compatible organic osmolytes responsible for 
equilibrating an increased intracellular tonicity (Cho, is believed to be also an osmolyte) 
(Danielsen & Ross, 1999).  The mI/Cr and Cho/Cr reduction was also reported by Kraft in 
one de novo WD patient with hepatic disease (Kraft E et al.,1999). In newly diagnosed WD 
patients a reduction of NAA/Cr in the pallidum of hWD patients was noted (Tarnacka et al, 
2009). This could indicate that in these patients, 1H-MRS detects a combination of early 
encephalopathic and neurodegenerative changes, if NAA can be considered a neuronal 
marker.  
Newly diagnosed WD patients with neurological impairment showed an increased level of 
Cho/Cr and Lip/ Cr in the pallidum and thalamus; furthermore, Glx/Cr was increased and 
NAA/Cr was decreased in the pallidum. The Cho peak is considered a potential biomarker 
for the status of membrane phospholipid metabolism (Danielsen &  Ross, 1999),  so that an 
elevated Cho signal most likely reflects an increase in membrane turnover. In pathologies 
characterised by membrane breakdown, such as neurodegeneration, bound Cho moieties 
may be liberated into the free Cho pool (Danielsen &  Ross, 1999). It is possible that the 
increase of Cho/Cr and Lip/Cr ratios in the pallidum and the thalami can reflect an increase 
in membrane turnover caused by free copper accumulation, or can be associated with gliosis 
because Cho is present in high concentrations in oligodendrocytes (Van der Hart et al., 
2000). In nWD patients, the increased level of Glx/Cr in the pallidum, can be related to the 
shunting of ammonia to the brain and glutamine accumulation. The elevation of Glx, can be 
also related to neuronal energy impairment. Removal of glucose greatly accelerates 
glutamate transamination to aspartate in brain synaptosomes, suggesting that glutamate 
could be an energy source in brain under some circumstances (Erecinska et al, 1988). 
Aspartate transaminase is the enzyme that accomplishes the task of glutamate 
transamination. It consumes oxaloacetate and glutamate to produce aspartate and alpha-
ketoglutarate, which can directly enter to the TCA cycle (Moffett et al, 2007). Most studies 
concerning the relationship between neurospectroscopic abnormalities and the neurological 
HE manifestation found an association between the presence of HE and Glx/Cr level (Kreis 
et al., 1992;. Cordoba et al., 2001). In nWD patients no other metabolite changes specific for 
HE such as mI/Cr and Cho/Cr reduction was detected, so it is conceivable that because of 
chronic liver failure, in nWD patients the compensatory mechanism to counteract 
intracellular hypertonicity can take place, with no mI depletion, but with an increase of Glx. 
This finding, could indicate, that in newly diagnosed nWD patients an HE could exist. 
Patients with liver cirrhosis do present with parkinsonian signs including: tremor, 
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bradykinesia, dysarthria, hypomimia, or rigidity. Some authors have speculated that the 
neurological symptoms of WD can be caused by concomitant liver disease (Victor, 1999).  
These MRS findings can prove that in newly diagnosed nWD patients in the brain a porto-
systemic shunting changes, but also neurodegenerative pattern associated with Cho, Lip 
and NAA/Cr depletion nWD can coexist. Verma compared brain metabolite alternations in 
patients with acute liver failure, acute-on-chronic liver failure and chronic liver disease 
(Verma et al, 2008). He found that NAA/Cr ratio was significantly decreased in  acute-on-
chronic liver failure and chronic liver disease. This fact can prove that in chronic liver 
disease an mitochondrial dysfunction can be detected due to neurotoxic effect. It is also 
worthy to mentioned that in patients with hepatic and neurological impairment in WD a 
significant negative correlation in the pallidum between the clinical status and the NAA/Cr 
was detected (Tarnacka et al, 2009).   
From the 37 patients newly diagnosed, we followed 17WD cases for more than one year 
period (Tarnacka et al, 2008). In the 1H-MRS done during the follow-up of all WD 
patients, significantly lower levels of mI/Cr and higher levels of Lip/Cr compared to the 
control group were persistently noted (Figure 5a).  In patients with hepatic signs with 
improvement, a statistically significant increase of mI/Cr and Glx/Cr in follow- up 1H-
MRS was observed (about one year post-treatment, Figure 5b). In patients with 
neurological improvement after treatment in the follow-up 1H-MRS, a statistically 
significant increase of NAA/Cr was noted (Table 5c). During neurological deterioration in 
one case, a decrease of Glx/Cr and NAA/Cr was seen, in contrast to another 
neurologically impaired patient with liver failure exacerbation, where a decrease of 
mI/Cr and increase of Glx/Cr was observed (Tarnacka et al, 2009).  
 
a. significantly lower than in controls (p<0.005),  
b. significantly higher than in controls (p<0.0001) and compared with first study p<0.005, 
c. significantly higher than in controls (p<0.005), 
(a) 
0,00
0,20
0,40
0,60
0,80
1,00
1,20
1,40
1,60
1,80
2,00
mI/Cr Cho/Cr Glx/Cr NAA/Cr Lip/Cr
WD First Study WD Second Study Control Group
      a      a 
      b 
a 
  c   c  
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a. significantly lower than in controls, p<0.005, 
b. significantly higher compared with first study p<0.04, 
c. significantly higher than in controls, p<0.00006 and compared with first study p<0.002, 
d. significantly higher than in controls, p<0.005 
(b) 
 
a. significantly lower than in controls, p<0.05, 
b. significantly higher compare with first study, p<0.01 
c. significantly higher than in controls, p<0.02 
(c) 
Fig. 5. The mean metabolic ratios in patients with improvement: a) all 15 WD patients  b)  
hepatic subgroup (n=9), c) neurological subgroup (n=6), in the first and second 1H-MRS test 
compared to the age-matched control subjects. Statistical analysis in text. 
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The alternations of NAA/Cr ratio in neurologically impaired patients and mI/Cr and 
Glx/Cr in patients with liver failure could be a sensitive marker of the clinical recovery and 
deterioration in those WD patients.  
A decrease in relative NAA concentrations has been observed in pathological processes 
known to involve neuronal loss (Rudkin & Arnold, 1999). NAA is synthesized by neuronal 
mitochondria, which are sensitive to injury (Bates et al., 1996). A reversible decrease of NAA 
could well be caused by mitochondrial toxin 3-nitropropionate (Dauntry et al., 2000).  
Mitochondrial proteins seem to be the target of copper toxicity, because a decrease in the  
 
 mI/Cr Cho/Cr Glx/Cr NAA/Cr Lip/Cr 
      
All  0.660.30 0.890.21a 1.350.20b 1.440.35 0.930.48c 
CS 0.830.14 0.750.16 1.090.31 1.610.22 0.450.18 
hWD   0.630.33 0.790.38 1.330.47 1.470.38 0.990.57d 
CS 0.660.14 0.760.16 1.090.31 1.580.22 0.430.18 
nWD  0.720.21 0.960.36e 1.360.44f 1.410.42 0.890.48g 
CS 0.950.41 0.750.12 1.090.23 1.630.28 0.460.22 
a. significantly higher than in controls (p<0.0002)     
b. significantly higher than in controls (p<0.0005)                                       
c. significantly higher than in controls (p<0.00002)  
d. significantly higher than in controls (p<0.000000)  
e. significantly higher than in controls (p<0.00002) 
f. significantly higher than in controls (p<0.004) 
g. significantly higher than in controls (p<0.0003)  
(a) 
 
 mI/Cr Cho/Cr Glx/Cr NAA/Cr Lip/Cr 
      
All 0.680.30 0.790.36 1.100.37 1.360.26a 0.940.31b 
CS 0.710.18 0.760.16 1.130.21 1.650.21 0.470.16 
hWD  0.640.22 0.580.21c 1.310.18 1.450.50 0.870.50 d 
CS 0.780.28 0.930.24 1.200.27 1.560.31 0.500.22 
nWD  0.750.34 1.030.30e 1.180.32 1.300.25f 0.860.29g 
CS 0.710.17 0.650.16 1.030.22 1.600.29 0.470.20 
a. significantly lower than in controls (p<0.01),  
b. significantly higher than in controls (p<0.003) 
c. significantly lower than in controls (p<0.001) 
d. significantly higher than in controls (p<0.0003)  
e. significantly higher than in controls (p<0.0003)  
f. significantly lower than in controls (p<0.002) 
g. significantly higher than in controls (p<0.003)    
(b) 
Table 2. The mean metabolites ratios compared with control subjects (CS) in all WD patients, 
in hWD and nWD subgroups in: a) patients with improvement of clinical status, b) patients 
with no improvement of clinical status.   
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levels of the subunits of some of the complexes of the respiratory chain occurs (complex I 
being the most affected) (Aricello et al., 2005). It is possible that in WD, functional changes in 
neurons affecting oxidative metabolism may result in the reversible changes in relative 
concentration of NAA are reported in those study here. These findings suggest, that the 
early diagnosis and treatment of WD patients can reduce neurons metabolic disturbances 
and avoid their degeneration process. It is a very useful information which can prove that in 
nWD patients with  improvement of clinical signs in the brain reversible functional changes 
of neurons could be detected.    
In WD patients treated for long time in nWD and hWD subgroups with improvement or no 
improvement of clinical status the MRS findings in Table 2 are provided (Tarnacka et al., 
2010). In those study we investigated 4 hWD patients, with no improvement and 8 with 
marked improvement; and 8 nWD patients with marked improvement and 7 with no 
improvement of clinical status. In hWD patients with improvement the MRS did not show 
any important pathological changes and in the nWD  with improvement significantly higher 
Cho/Cr, Glx/Cr and Lip/Cr ratios levels compared with controls were noted (Table 2a). In 
hWD patients with no improvement the lower Cho/Cr  and in nWD significantly lower 
NAA/Cr and higher Cho/Cr and Lip/Cr ratios were detected (Table 2b). 
In all WD patients who showed improvement after treatment, MRS revealed a higher level 
of Cho/Cr, Glx/Cr and Lip/Cr ratios. In our previous study, we demonstrated a decrease in 
NAA/Cr ratio in all symptomatic patients, which increased after one year of treatment 
(Tarnacka et al, 2008).  In patients treated for a longer time with improvement of clinical 
status no NAA/Cr decrease was seen; this could suggest that in WD patients the NAA/Cr 
depletion is reversible during the first few years of treatment and that treatment with z-s or 
d-p can protect them from further WD progression. The Cho/Cr and Glx/Cr elevation 
may mirror the glial proliferation that can be detected in patients even after long-term 
treatment (Horoupian et al., 1988). In this study, the persistence of NAA/Cr was related 
to a lack of improvement in neurological status (Tarnacka et al., 2010), what is in 
concordance with earlier reports in the literature showing a lower level of NAA in the 
striatum in neurologically impaired patients who received treatment (Page et al,.2004;  
Lucato et al., 2005). The lower level of NAA/Cr in the pallidum in these patients may 
suggest that, in patients with neurological involvement, persistent neuronal dysfunction 
may occur as a result of copper and/or iron deposition. NWD patients with no 
improvement initially had lower ceruloplasmin levels compared with those in whom 
neurological recovery was noted. It is possible that in these patients the iron metabolism 
could also be disturbed because of ceruloplasmin deficiency, which can be enhanced 
during chelation treatment (Medici et al.,2007).  
2.1.1 MRS in heterozygous WD gene carriers 
Wilson’s disease a genetic disease due to mutation of both alleles of “Wilson’s disease” gene 
ATP7b. The number of heterozygotes – having only one faulty copy of the gene – is high, 
around 1-2% of the human population (Johnson, 2001). Heterozygote carriers should not 
have symptoms of hepatic, neurological dysfunctions, but in other recessive disorders such 
as phenyloketonuria, some deviations in brain function in the literature were reported 
(Vogel, 1984). Because 1 H-MRS is able to detect brain abnormalities that are invisible in 
clinical assessment and MRI a study using this method to investigate the probability of brain 
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changes in Hzc was performed (Tarnacka et.al, 2009b). We observed statistically significant 
higher ratios of Glx/Cr and Lip/Cr in 1 H-MRS in Hzc in the pallidum (Table 3). Glx is a 
glial marker; the increase of Glx/Cr could correlate with the glial proliferation as a result of 
the protective function of the astrocytes to copper and iron accumulation. The significantly 
higher level of Lip/Cr may reflect the liberation of lipids from membranes during their 
breakdown as a reaction to copper and iron overload. Our results may instead suggest that 
WD Hz carriers accumulate free copper or iron or both in basal ganglia and thalami. Hzc in 
our study were much older than WD cases are and in an animal model of WD copper and iron 
levels were found to be augmented during aging in striatum and substantia nigra (Kim et al., 
2001). It is possible that during aging in Hz there is an increase of copper and iron 
accumulation because of ATP7b and ceruolplasmin impairment. There is accumulating 
evidence that ceruloplasmin, a copper protein with ferroxidase activity, plays an important 
role in iron metabolism and is also the principal plasma copper-binding protein (Harris et al., 
1998). In our Hz  the ceruloplasmin level was lower in only four cases, but ceruloplasmin 
levels in the blood are influenced by acute-phase reactions. The copper accumulation in the 
brain can also be caused by disruption in its excretion. In animal models, heterozygous mice 
have a reduced ability to excrete copper, which may indicate that half of the normal liver 
ATP7b copper transporter activity is insufficient to deal with a large amount of copper intake 
(Cheach et al., 2007).  Like iron, copper is a heavy metal that can induce the Fenton reaction via 
production of free radicals and copper and iron accumulation increased with aging might 
have deleterious of liver and brain via oxidative stress.  
 
 mI/Cr Cho/Cr Glx/Cr NAA/Cr Lip/Cr 
1 H-MRS study 
Gp 
Hz: 
 
0.730,19 
 
0.810,13 
 
1.380,30* 
 
1.50,28 
 
0.960,40** 
Control 
subjects 
 
0.82  0,82 
 
0.78  0,16 
 
1.11  0,26 
 
1.62  0,27 
 
0.48  0,20 
 
1 H-MRS study 
Th 
Hz 
 
 
0.90  0,27 
 
0. 95  0,23 
 
1.44 0,40¥ 
 
1.93 0,35 
 
1.08 0,40¶ 
Control subjects 0.82 0,21 0.84  0,15 1.12  0,21 1.69  0,25 0.51  0,20 
*significantly higher than in controls, p<0.00006 
** significantly higher than in controls, p<0.00002 
¥ significantly higher than in controls, p<0.0006 
¶ significantly higher than in controls, p<0.000001 
Table 3. The mean metabolites ratios in heterozygotes (Hz) and control subjects from left 
and right globus pallidus (Gp) and right and left thalamus (Th) with standard deviations.   
2.1.2 MRS versus Wilson’s disease treatment  
The treatment of WD patients may take many forms, from drug therapy (chelating agents as 
d-penicillamine (d-p) or trientine, zinc therapy, tetrathiomolibdate) to liver transplantation 
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(LT). The aim of medical treatment for WD is to remove the toxic deposit of copper from the 
body to produce a negative copper balance, and to prevent its reaccumulation. Successful 
therapy is measured in terms of a restoration of normal levels of free serum copper and its 
excretion in the urine. In 9 patients treated for more than one year with d-p in author’s 
preliminary study, statistically significant increase of Glx/Cr and NAA/Cr ratios was 
noticed in contrary to 8 patients treated with zinc sulphate (z-s) were decrease of ml/Cr and 
NAA/Cr was detected (Figure 6a,b). D-penicillamine seams to be more effective (increase of 
NAA/Cr) during one year treatment, compared with z-s, but those study was performed on 
a quite small sample of patients. Those findings can also confirm Brewers observations, that 
zinc compounds are slow acting drugs and the decrease of mI/Cr can reflect the metabolic 
deterioration during zinc therapy (Brewer, 2005).  
Current therapeutic strategies are often effective in the treatment of WD and provide a 
negative copper balance, however the course of WD in some treated patients may be 
unpredictable (Członkowska et al., 2005). The effectiveness of chelation or zinc therapy 
should therefore be monitored. So far, the only useful tests of monitoring the treatment 
efficiency are laboratory and imaging methods. Biochemical tests used in monitoring WD 
treatment include plasma liver tests, caeruloplasmin, copper and zinc in serum, and 
urinary copper and zinc excretion tests. These methods may sometimes be not sufficiently 
in particular at the beginning of the treatment when most of treatment side-effects occur 
as iatrogenic worsening during d-p therapy. In this stage wee postulated that 1H-MRS can 
be used in early stages of treatment monitoring when the alternations of NAA, mI and 
Glx can mirror therapeutic response or deterioration (Tarnacka et al, 2008). We think that 
1H-MRS can also be helpful in differential diagnosis of clinical deterioration in patients 
with WD. 
In patients with progressive liver failure or acute liver failure from fulminant hepatitis with 
or without intravenous hemolysis, orthotropic hepatic transplantation is an efficient 
treatment (Hoogenraad, 1997). Hepatic transplantation is also indicated in the absence of 
liver failure in patients with neurological WD in whom chelation therapy has proved 
ineffective, and significant improvements in neurological features have been reported 
(Polson et al., 1987). We presented a study of spectroscopic changes in globus pallidus in 3 
patients with WD undergoing LT. The first case was a patient with neurological and hepatic 
impairment who was undergoing LT because of liver cirrhosis exacerbation. The second and 
third patients were subjects only with hepatic signs and the LT was performed because of 
liver failure. In the patient with neurological signs the MRS was performed 4 months after 
LT because there was no neurological improvement, and again one year after that. In the 
first MRS in those patient there was an increase in Glx/Cr, NAA/Cr and Lip/Cr ratios 
levels compared with the controls (Figure 7a). After one year’s observation time an 
improvement of clinical status was observed and no changes of metabolites ratios were 
seen(Figure 7a). Before LT in the patient with liver cirrhosis mI/Cr ratio level was very low, 
in both patients with liver failure a decreased level of Glx/Cr, NAA/Cr and increased 
Lip/Cr ratios levels compared with controls were found (Figure 7b,c). After LT in those 
patients an increase of mI, Glx/Cr and NAA/Cr was seen (Figure 7.bc). Those data provide 
that  after LT in those WD patients a renormalization of brain metabolites changes detected 
in 1 H-MRS could be seen.   
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a. statistically higher than in controls ( p<0,0003), 
b. statistically  higher than before treatment (p<0,01), 
c. statistically  higher than in controls (p<0,00004), 
a) 
 
a. significantly higher than in controls  (p<0,003), 
b. significantly higher than in controls  (p<0,0002), 
c. significantly higher than in controls  (p<0,001). 
b) 
Fig. 6. The mean metabolites ratios before treatment with d-p (a) and z-s (b), after minimum 
one year of treatment and in control subjects.  
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c) 
Fig. 7. The mean metabolites ratios in globus pallidus in 3 patients undergoing liver 
transplantation, in first patient a) second- b) third- c), explanation in the text.  
3. Conclusion  
In conclusion, the results of the present studies appear to prove that in WD the astrocytic 
abnormalities occur primarily with dysfunction of the astrocytic-neuronal interactions. This 
process leads to metabolic derangement in neurons. During the disease progression and 
increasing copper deposition in the brain the compensation reactions as metallothionein 
synthesis become inefficient and the degenerative changes of astrocytes prevail over their 
detoxicative possibilities. The copper liberates from damaged astrocytes, and can also 
damage the neurons directly. Free copper can induce the neuronal mitochondria 
dysfunction causing the impaired NAA synthesis, but on this stage the destructive process 
can be reversible, because the increase of NAA/Cr can be observed in most treated patients. 
This is a very important conclusion, because it shows that the first year of treatment are 
pivotal in the therapeutic process. In majority of patients in this stage the central nervous 
system damage can be reversible. These findings emphasize the need for early diagnosis 
and treatment of WD.  Effective antioxidant therapy introduced in early stages of WD 
might have modifying effect of metabolic disturbances in neurons. The neuronal 
dysfunction lasting longer can cause non reversible degenerative process like in patients 
treated for long time with no neurological improvement. Irreversible astrocytic 
dysfunction caused by copper can be related with disturbed ceruloplasmin synthesis 
causing iron overload and lead to lack of neurological improvement in some WD patients. 
The 1H-MRS technique can be useful in treatment monitoring in patients with WD in early 
stages (until one year).  MRS seems to be more effective method in comparison with MRI 
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in monitoring effectiveness of treatment during first year. MRS could be helpful in 
differential diagnosis of the clinical deterioration in treated WD patients.  The alternations 
of NAA/Cr ratio in neurologically impaired patients and mI/Cr and Glx/Cr in patients 
with liver failure could be a sensitive markers of the clinical recovery and deterioration in 
those WD patients. MR spectroscopy could be a useful complementary tool in other 
monitoring treatment methods in WD patients.    
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